Cadila Healthcare Ltd: Company Overview
Cadila Healthcare Ltd, also known as Zydus Cadila, is a prominent Indian pharmaceutical company founded in 1952. Headquartered in Ahmedabad, Gujarat, the company has undergone significant expansions and strategic partnerships over the years. With a strong legacy and diverse portfolio, Cadila Healthcare Ltd continues to make strides in the pharmaceutical industry.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Assignment Presentation on Cadila Healthcare Ltd Prepared By : MET Rahul Patil (B275) Under Guidance Of : Jitendra Sir And Ramashish Sir Aditya Birla Sun Life Insurance
Cadila Healthcare Ltd. Profile Cadila Healthcare Ltd (Zydus Cadila) (BSE: 532321) is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat, India. Cadila was founded in 1952 by Ramanbhai Patel. In 1995 the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals Ltd., and Cadila Healthcare Ltd became the Patel family's holding company. The Company was converted into a public company and then renamed as Cadila Healthcare Ltd. effective from Juy 17, 1996. In the year 1996, the company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India
In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2003, German Remedies, Recon Healthcare, Zoom Properties and Zydus Pathline merged with the company. During the year 2005-06, the company signed a 50:50 joint venture with one of India's top biotech companies Bharat Serums and Vaccines Ltd (BSV) and formed Zydus BSV Pharma Pvt Ltd to develop During the year 2006-07, the company entered into share purchase agreement to acquire 97.95% stake in Liva Healthcare Ltd In 2010, Cadila Healthcare received a Wellcome Trust Award under the "R&D for Affordable Healthcare in India" initiative.
Founder Of The Company Ramanbhai B. Patel (19 August 1925 19 September 2001) Education : Studied chemistry at Gujarat University's L.M. College of Pharmacy before becoming a lecturer there. Ramanbhai was one of the stalwarts of the Indian pharmaceutical industry Awards : 1. The President of India's Import Substitution Award in 1973 for inventing a new process technology for Glibenclamide. 2. Prof M L Shroff Memorial National Award in 1987. 3. The Glory of India Award in 1991 in Washington, Grahak Suraksha Award in 1992, Acharya Prafulla Chandra Ray Memorial Gold Medal in 1993, the Eminent Pharmacist Award in 1994 4. The Gujarat Chamber of Industry and Commerce's Gujarat Businessman of the Year Award in 2000.
CEO Of The Company Pankaj Ramanbhai Patel (born 1951) Education : Holds Bachelor Pharmacy degrees from Gujarat University, as well as a BA in Science and Law from the University of Mumbai. Industrial Experience (44years) : Patel joined the firm in 1976 and took charge in 1995 after a formal separation between the two founding families. of Pharmacy and Master of
Pharmaceuticals Sector Overview Market Size : Indian pharmaceutical sector is expected to grow to US$ 100 billion and medical device market expected to grow US$ 25 billion by 2025. Pharmaceuticals exports from India stood at US$ 19.14 billion in FY19 and US$ 13.69 billion in FY20 (up to January 2020) Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in UK. The drugs and pharmaceuticals sector attracted cumulative FDI inflows worth US$ 16.25 billion between April 2000 and June 2019 Medicine spending in India is projected to grow 9-12 per cent over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.
Advantages of Pharmaceuticals Sector Companies In India
Cadila Healthcare Ltd. Good : 1. Cadila has a well-built image of excellence and innovation. 2. It has a well logistics and distribution channel network. 3. Offering new products to the customers continuously. BAD : 1. Equal importance is not given by distributors to all retailors. 2. No training schedules for training of distributors salesman. 3. No regular audit of the distributors.
Products And Brands Products : Cadila Healthcare products covers Therapeutic Segments like Anti-Infective, Anti-Epileptic, Anti-Allergic, Anti- Depressant, Gastrointestinals, Anti-Osteoporosis, Sedative, Women's Healthcare, Anti-Rheumatic, Anti-Diabetic, Anti- Psychotic, Tranquilizers, Pain Management and Tadalafil. Brands : Oflin OD, Clodus, NeoLoridin, Ven-OD, Isbis, Bonmax, Cartup, Zyquin, Oxeptal, Zytonin, Cefinar, Zycolchin, Dactive, Vageston, Xet, Aldren, Serlin, Mexate, Epsolin, Euglim, Olandus, Divalpro, Topiram, Cytolog, Stilnite, Mifegest, Linid, Mosadac, Espra, Salazar, Lamidus, Zoldac and Zydalis.
Speciality Cadila Healthcare Ltd is a well known research-oriented technology-driven pharmaceutical company focused on the research areas of biotechnology formulations and Active Pharmaceutical Ingredients. As one of the key players amongst the pharmaceutical manufacturing companies, the group has manufacturing capabilities across the entire pharmaceutical value chain: including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products and wellness products. It has more than 30 manufacturing plants worldwide including India, Brazil and USA.
Zydus Wellness distribution in India has witnessed a paradigm shift. Before 1990, pharmaceutical companies established their own depots and warehouses. Now they have been replaced by clearing and forwarding agents (CFAs). Zydus Wellness has two types of channel selling i. Regular (traditional) retail channel, ii. Direct Selling Channel in the name of Zydus Wellness Network . Typically, the goods produced in each of the ZYDUS WELLNESS's 40 factories are sent to a depot with the help of a carrying and forwarding agent (C&FA). The company has its depot in every state of the country.The C&FA is a third party and gets servicing fee for stock and delivery of the products. In each town, there is at least a redistribution stockist (RS) who takes the goods from the C&FA and sells them to retail outlets.
Reach of Cadila Healthcare Ltd. : Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil. Zydus global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide. Employee Highlight : 12,196 employees work for Zydus Cadila .
Financial Highlights ( In Rs Crores) FY2017 FY2018 FY2019 Debt 5207 5407 7899 Sales 9376 11,905 13,166 Operating Cost 7474 9076 10,192 EBITDA 2275 3368 3572 Depreciation 373 539 599 EBIT 1902 2829 2973 Interest 45 91 194 EBT 1612 2312 2382 Tax 128.96 554.88 524.44 EAT 1488 1776 1849
Financial Highlights( In RS Crores) FY2017 FY2018 FY2019 EPS 8.91 13.51 19.06 Friday s Closing Price 331.80 (on NSE) As on 15 May 2020 PE Ratio 27.21 Price To Book Value 6.86 5.01 3.96 EV/EBITDA 53.26 22.24 16.19 Free cash Flow -247 167 -78 Current Ratio 1.07 1.27 1.71 Debt to Equity Ratio 0.33 Interest Coverage Ratio 42.26 31.08 15.32
News Related to Company Share market update: Pharma shares gain; Cadila Healthcare climbs 5%(14 May 2020) Cadila Healthcare Ltd.Statement Of Investor Complaints For The Quarter Ended March 2020 ( 11 May 2020) Cadila Healthcare Ltd.Compliance For The Half Year Ended On On March 31, 2020 (11 May 2020)
Impact of Corona Rising price of drugs : India s manufacturers rely heavily on imports of their APIs from China. Lack of supply of active pharmaceutical ingredients or finished drug products from China: The pharmaceutical companies faces disruptions due to extended factory closures in China. Inter State Transport Challenges: Inter-state transport challenges is also an major issue. There is a lot of medicine stock that comes from Goa, Baddi and Sikkim. Due to the lockdown, it has become difficult to reach the retailers.
My Views Pros: Company has been maintaining a healthy dividend payout of 20.53% Cons: Company might be capitalizing the interest cost
